ReviewNature reviews. Clinical oncology2025
Leptomeningeal metastatic disease: new frontiers and future directions.
Review in Nature reviews. Clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.Nature medicine · 2025Trial
- Probable cavernous sinus-adjacent meningeal metastasis from esophageal squamous cell carcinoma: A case report.Oncology letters · 2026Article
- Prognostic value of the Evans index in neoplastic meningitis: a real-world cohort study.Journal of neuro-oncology · 2026Article
- Review
- Tumor-Associated Macrophages Promote Brain Metastasis.bioRxiv : the preprint server for biology · 2026Article
- Article
- A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche.Nature cancer · 2026Article
- Central Nervous System Involvement in Acute Myeloid Leukemia: From Pathophysiology to Neuroradiologic Features and the Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
- Article
- [Chinese Expert Consensus on Clinical Management of Oncogene Addicted Non-small Cell Lung Cancer with Leptomeningeal Metastasis (2026 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.Frontiers in oncology · 2026Review
- A rare case of Lung adenocarcinoma complicated with leptomeningeal and brain parenchymal metastasis: case report and review of the literature.Frontiers in oncology · 2026Article
- Cytopathological Findings of Axillary Lymph Nodes in Patients with Breast Cancer in Correlation with Ultrasound Findings.Iranian journal of pathology · 2026Article
- Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes.Brain & spine · 2026Article
- The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- Point/Counterpoint: Intrathecal therapy for patients with leptomeningeal metastases from solid tumors.Neuro-oncology · 2025Article
- Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study.The oncologist · 2025Article
- Outcomes of leptomeningeal disease after only vertebral osseous metastases: a real-world analysis using the TriNetX database.Journal of neuro-oncology · 2025Article
- TUXEDO-3: A phase 2 trial of patritumab deruxtecan for patients with leptomeningeal metastasis.Neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastatic disease (LMD), encompassing entities of 'meningeal carcinomatosis', neoplastic meningitis' and 'leukaemic/lymphomatous meningitis', arises secondary to the metastatic dissemination of cancer cells from extracranial and certain intracranial malignancies into the leptomeninges and cerebrospinal fluid. The clinical burden of LMD has been increasing secondary to more sensitive diagnostics, aggressive local therapies for discrete brain metastases, and improved management of extracranial disease with targeted and immunotherapeutic agents, resulting in improved survival. However, owing to drug delivery challenges and the unique microenvironment of LMD, novel therapies against systemic disease have not yet translated into improved outcomes for these patients. Underdiagnosis and misdiagnosis are common, response assessment remains challenging, and the prognosis associated with this disease of whole neuroaxis remains extremely poor. The dearth of effective therapies is further challenged by the difficulties in studying this dynamic disease state. In this Review, a multidisciplinary group of experts describe the emerging evidence and areas of active investigation in LMD and provide directed recommendations for future research. Drawing upon paradigm-changing advances in mechanistic science, computational approaches, and trial design, the authors discuss domain-specific and cross-disciplinary strategies for optimizing the clinical and translational research landscape for LMD. Advances in diagnostics, multi-agent intrathecal therapies, cell-based therapies, immunotherapies, proton craniospinal irradiation and ongoing clinical trials offer hope for improving outcomes for patients with LMD.
Indexed as
Identifiers
39653782What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.